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Abstract 
 
This paper reports the structure elucidation and characterization of 4-chloromethamphetamine 
(4-CMA), a compound never previously reported outside of laboratory settings in seized drug 
samples or substances actively being used at large dance festivals. 
Identification of 4-CMA was obtained by liquid chromatography with diode array detector 
(HPLC-PDA) and gas chromatography mass spectrometry (GC-MS). Further structure 
elucidation was performed by fragment pattern analysis of the trimethylsilyl and trifluoroacetyl 
derivatives with GC-MS. The regio-isomeric assignment of the chloro-substituent was performed 
by 1H nuclear magnetic resonance spectroscopy (1H-NMR).  HPLC-PDA was used for 
quantitation of 4-CMA in the seized tablet to obtain an indication of the potency.  
A literature review of the toxic effects of 4-CMA and potential widespread harm to the public in 
events where similar substances or tablets start appearing and circulating on a larger scale in the 
general population is discussed. 
Keywords: 4-chloromethamphetamine (4-CMA), identification, elucidation, NPS, (neuro)toxic, 
ecstasy 
 
  
1. Introduction 
Large changes have occurred in the recreational drug market in Europe over the last decade, 
which can be roughly divided in two general phenomena: high dose ecstasy, and arrival of new 
psychoactive substances (NPS).  
First, since the end of the ‘90s and the beginning of 2000, the appearance of a plethora of NPS 
designed to evade current international drug legislation was observed. Examples include the 
advent of mephedrone around 2010 and synthetic cannabinoids since approximately 2005; the 
latter still play a predominant role in the rapidly evolving ‘legal highs’ market and are 
responsible for a large increase in the detected number of new substances.  
Second, as a result from legislation and precursor shortages due to increased seizures, the 
average MDMA content in ‘ecstasy’ tablets was historically low around the early 2000’s in 
Belgium, resulting in low-dosed ecstasy tablets, which were often contaminated with other 
substances such as piperazines (e.g. mCPP). As illustrated in Figure 1, mean MDMA dosages of 
around 60 mg (expressed as MDMA base) were observed until 2009, followed by an increase to 
92 mg. Dosage further increased and reached a mean of 108 mg in 2013. The highest recorded 
dosage was observed in 2014 (125 mg) (1).  
 
Figure 1. Evolution of MDMA dosage in ecstasy tablets in Belgium (2005 – 2016). 
 
 
These historically low dosages coincided with the arrival of NPS (Figure 2). Partly because of 
the scheduling of substances such as MDMA, derivatives were designed with similar chemical 
structure that retained the psychoactive properties of the original molecule, but remained legal to 
manufacture and sell. Most of these substances are sold in smart shops or online as “bath salts”, 
“carpet cleaner”, “plant food”, “legal highs”, and “research chemicals”, and labeled not to be 
suited for human consumption. 
 
Figure 2. Evolution of number of NPS detected in Belgium each year (2004 – 2016). 
 
NPS encompass a wide range of psychoactive compounds, including synthetic phenethylamines, 
cathinones and synthetic cannabinoids. By the end of 2016 more than 500 unique NPS 
compounds had been identified by the Early Warning System of the European Centre for Drugs 
and Drug Addiction (EMCDDA) (2). Since most of these substances have never been studied 
formally, and (toxic) effects in humans are mostly unknown, NPS constitute a real danger to 
public health, especially in the last three years when derivatives of fentanyl (“fentalogs”) have 
started to appear on the market. Also, due to the lack of analytical reference standards, 
identification and general analysis of these substances poses a significant challenge in forensic 
toxicology.  
In some cases NPS “cross-over” from the online scene is observed, meaning NPS entering the 
“classic” illicit drugs market where they are sold by the same dealers; for example 4-
fluoroamphetamine is frequently encountered in this fashion (3). Other NPS have been found in 
ecstasy tablets or in powders sold as heroin and amphetamine (4–6). In almost all cases the user 
is unaware of their presence, thinking instead he or she received a “weak” batch of the wanted 
drug. This carries great risk; one example in Belgium and The Netherlands was the 
contamination of amphetamine/speed with 4-methylamphetamine, a NPS with strong 
serotonergic action. At least six people have died in Belgium as a result of the consumption of 
this amphetamine mixture (7). Another widespread example is the presence of CMA and PMMA 
in ecstasy tablets (Figure 3), which has led to dozens of deaths worldwide (8,9).  
 
During the summer of 2015 an ecstasy tablet was submitted to the laboratory for identification. 
In this paper, firstly we present the identification and structure elucidation of the unknown 
molecule in the confiscated tablet using GC-MS, HPLC-PDA and 1H-NMR. Secondly, we will 
report on potential (neuro)toxic effects and potential widespread harm to the public in events 
where similar substances or tablets start appearing and circulating on a larger scale in the general 
population. 
 
2. Materials and methods  
2.1 Samples and case histories 
Several tablets confiscated by federal police in the framework of an international electronic 
music festival in Belgium were submitted to the laboratory for toxicological analysis. Based on 
physical properties, eight different tablets could be distinguished. One of the tablets was 
rectangular, yellow/brown (non-uniform colour), ‘durex’-logo on one side and single-scored on 
the other side (weight: 427.1 mg; length:12.51 mm; width: 4.29 mm; height: 8.44 mm). The 
other tablets in the seizure (with different physical characteristics) were found to contain 
MDMA, MDMA, sildenafil/tadalafil, MDMA, MDMA, DOB and MDMA, respectively.  
2.2 Materials 
Certified reference components and general chemical reagents were obtained from Cayman 
Chemical (Michigan, USA). Solvents used for GC-MS and HPLC-PDA were of analytical grade. 
Methanol, acetonitrile and hydrochloric acid (37 %) were obtained from Fisher Chemical (Fisher 
Bioblock, Belgium). Water was purified by a Milli-Q system obtained from Merck Millipore 
(Darmstadt, Germany). Triethylammonium (TEA) phosphate 1 M was purchased from Sigma 
(Zwijndrecht, Belgium) and was diluted 1/40 immediately before use. The external standard 
diphenylamine was obtained from VWR International (Leuven, Belgium). N-methyl-N-
(trimethylsilyl) trifluoroacetamide (MSTFA) and N-methyl-bis(trifluoroacetamide) (MBTFA) 
were purchased from Machery-Nagel (Germany). NMR analysis and associated sample 
preparation: deuterated solvents for NMR were purchased from Euriso Top (St. Aubain, France). 
Tetramethylsilane was of NMR grade and was acquired from Acros Organics (Geel, Belgium). 
Dichloromethane was purchased from Sigma-Aldrich and was of HPLC grade. Hydrochloric 
acid and sodium hydroxide were purchased from Acros Organics (Geel, Belgium) and were of 
ACS grade. Ultrapure water was obtained from a Millipore Synergy UV apparatus (Billerica 
MA, USA).  
 
2.3 Sample preparation and instrumentation 
2.3.1 Gas chromatography-mass spectrometry (GC-MS) 
 
A fresh sample solution of 4-CMA in methanol (containing 200 µg/ml diphenylamine as external 
standard) was prepared. A mass spectrum was recorded by injecting a sample aliquot on an 
Agilent 6890 N gas chromatograph in combination with an Agilent 7683 injector and an Agilent 
5973 inert mass selective detector (Agilent Technologies, California, USA). Mass spectra were 
recorded using a Varian CP-SIL 8 CB low bleed capillary column (30 m x 0.25 mm, 0.25 µm 
film thickness) connected to a fused silica retention gap (2.5 m x 0.25 mm). The used carrier gas 
was helium at a constant flow of 1.1 ml/min. The temperature gradient was applied: starting at 70 
°C with 2 min holding time; increase to 310 °C at 8 °C/min with a 9 min holding time. Total 
runtime was 41 min. Injection port and detector temperatures were set at 300 °C and 230 °C 
respectively; transfer line temperature was set at 280 °C. An injection volume of 1 µL was used 
in split less injection mode. Mass spectra were recorded in the range m/z 40-550.  
For further structure elucidation, trimethylsilyl- (TMS) and trifluoroacetyl- (TFA) derivatives 
were prepared by evaporation of the methanolic extract at 40 °C under a gentle stream of 
nitrogen and subsequent heating in a sealed glass vial at 70 °C for 30 minutes in the presence of 
100 µl MSTFA or 100 µl MBTFA, respectively. Obtained derivatives were evaporated to 
dryness and reconstituted in acetonitrile. Subsequent analysis was performed using the 
procedures and protocols outlined in the GC-MS methods mentioned above. 
2.3.2  Liquid chromatography with photo-diode array detection (HPLC-PDA) 
The tablet was extracted with a freshly prepared methanol and subsequent evaporation of the 
methanol under a gentle nitrogen taking care stream not to let temperature rise higher than 40° C. 
A 50 µl aliquot was evaporated to dryness at 40 °C under nitrogen, and the powder was 
reconstituted in 1.0 ml of mobile phase A. Mobile phases consisted of 25 mM TEA-phosphate 
buffer (A) and 100% acetonitrile (B). The gradient used during elution consisted of 95% A at 
time 0, changing to 30% A in 30 min and held there for another 5 min. 
HPLC-PDA analysis was performed using a Varian Prostar solvent delivery module in 
combination with a Varian Prostar 410 autosampler and Varian Prostar photodiode array 
detector. Data acquisition and analysis were performed with the Varian Star and Polyview 
software. A LiChrospher® 100 RP-18 (5 µm) (Merck, Darmstadt, Germany) was used as 
saturation column. Separation of compounds was performed in gradient mode using a Microsorb 
C18 column (150 mm x 4.6 mm, 5 µm particle size, Agilent, California, USA) connected to a 
C18 guard column (4 mm x 3.0 mm, 3.5 µm particle size). Oven temperature was set at 35 °C. 
Scan range was 220-340 nm and the chromatogram was monitored at 220 nm and 254 nm for 35 
minutes. The injection volume was 50 µl.  
For quantitative analysis a stock solution of 1mg/ml in methanol was prepared immediately prior 
to use. A 30 mg aliquot of the homogenized powder of the tablet was weighted in a 10 ml 
volumetric flask and made up to volume with methanol: respectively 25 µl, 50 µl and 75 µl of 
methanolic extracts (sonicated for 30 min, homogenized and centrifuged) were transferred into 
an autosampler vial, dried under a stream of nitrogen after addition of 50 µl 10 % hydrochloric 
acid in methanol, and finally reconstituted in 1.0 ml initial mobile phase containing an additional 
20 µg/ml diphenylamine as external standard. A calibration series was used by transferring 10 µl, 
20 µl, 50 µl, 75 µl and 100 µl of stock solution into an auto sampler vial, which were 
subsequently dried under a stream of nitrogen (after addition of 50 µl 10 % hydrochloric acid in 
methanol) and reconstituted in 1.0 ml initial mobile phase containing 20 µg/ml diphenylamine as 
external standard. 
2.3.3  1H nuclear magnetic resonance spectroscopy (NMR) 
For the NMR analysis, the active component needed to be isolated from the yellow tablet. Since 
amphetamines are amines with a pKa of approximately 10, an acid/base extraction procedure 
was estimated to be suitable. To this end, a fragment of the tablet was placed in a glass test tube 
to which 10 mL water was added. The tube was sealed with a polypropylene cap and agitated 
until the material was mostly dissolved and only minor amounts of precipitate persisted. This 
suspension was transferred to a separatory funnel. The tube was rinsed thoroughly with 2 mL 
water. The pH of the solution in the separatory funnel was adjusted to 2-3 (Merck indicator 
paper) using 2.0 M HCl. The remaining solids of the suspension did not go into solution upon the 
addition of HCl. The aqueous suspension was washed with dichloromethane (3 x 20 mL). These 
dichloromethane fractions were discarded. The pH of the (acidic) aqueous fraction was adjusted 
to 12-13 by the dropwise addition of 4.0 M NaOH. At this pH the amine group in the 
amphetamine is expected to be in the free base form, which allows extraction into an organic 
solvent. The aqueous layer was thoroughly extracted with dichloromethane (5 x 20 mL). The 
dichloromethane fractions were pooled, dried using Na2SO4, filtered and concentrated in vacuo. 
A minimal amount of an oily residue was obtained. This material was stored under vacuum (~ 1 
mBar) in an attempt to remove all volatile impurities. The residue was dissolved in 1 mL CDCl3 
(+ 0.5% v/v TMS (tetramethylsilane)). From this solution 750 µL was transferred to an NMR 
tube which was closed with a polypropylene cap. 
All NMR spectra were recorded at 25 °C on a Varian Mercury-300BB (300/75 MHz) and 
processed using the Varian VNMRJ 3.2 software package.2.3. A solution of the material (± 20 
mg) in CDCl3 + 0.5% v/v TMS (750 µL) was prepared in an NMR tube (5 mm diameter, VWR-
300 MHz grade) and sealed using a polypropylene cap. The spectrum was recorded at 300 MHz 
using 32 scans and was referenced to the signal of TMS at 0 ppm. 
3. Results 
3.1. GC-MS 
A methanolic sample solution of the tablet was analyzed by GC-MS and the major peak was 
identified as 4-chloromethamphetamine (4-CMA) by means of computer-based library search 
and matching with the SWGDRUG Mass Spectral Library (Version 3.1). The mass spectra are 
shown in Figure 5.  
 
Figure 5. Mass spectrum of 4-CMA in the chromatogram from the tablet (upper) and reference 
mass spectrum of 4-CMA present in the SWGDRUG library (lower). 
 
Fragment pattern analysis of 4-CMA, TMS and TFA derivates confirmed the presence of a 
chloromethamphetamine regioisomer. Proposed fragmentation patterns of 4-CMA, TMS and 
TFA derivates are given in Figure 6. 
 
Figure 6: Proposed fragmentation pattern of 4-CMA (A), 4-CMA TMS derivate (B) and 4-CMA 
TFA derivate (C). 
 
3.2. HPLC-PDA 
In the chromatograms of the HPLC-PDA analysis, a peak was observed with the same retention 
time (± 2%) and UV spectrum (similarity index > 0.995) as 4-CMA. The HPLC-PDA 
chromatogram of the tablet with UV-spectrum of 4-CMA is shown in Figure 7. Calibrators and 
sample extracts were analyzed in one batch. A six-point calibration curve was made by plotting 
the ratio of the observed peak area of 4-CMA to this of the external standard diphenylamine to 
the amount of 4-CMA in the autosampler vial. The calibration curve was linear over the 
concentration range investigated (r: 0.9969). Residual plots were evaluated, confirming that the 
used calibration model was appropriate (criteria: 10%). Two aliquots were extracted. All results 
were within the calibration range and concentrations were calculated from the linear regression 
equation, taking in account the amount of aliquot extracted. The following mean concentration 
was measured: 98 mg 4-CMA (as base)/tablet (n= 6; range: 86 – 106 mg/tablet). A blank was 
analysed before every sample. No carry-over was observed. 
Figure 7: HPLC-PDA chromatogram of the tablet (upper) with UV-spectrum of 4-CMA (lower). 
 
 
 
 
 
 
 
 
 
 
 
3.3. 1H NMR 
For chloromethamphetamine, with respect to the position of the chlorine atom, three region-
isomers are possible, respectively 2-chloromethamphetamine, 3-chloromethamphetamine and 4-
chloromethamphetamine. The signals for the protons of the phenyl group can be found in the 
area between 6.5 - 8.0 ppm in the 1H-NMR spectrum. The peaks are shown to be two doublets, 
each with an integral of approximately 2, indicating the presence of a clear para-substitution. A 
full assignment of all the peaks of the 4-CMA structure can be found in Figure 8 and Figure 9.  
 
Figure 8: A: Three regioisomeric forms of chloroamphetamine B: Only 4-CMA has the required 
symmetry to yield the two doublets at 6.6 - 8.0 ppm. 
Figure 9. 1H-NMR spectrum of 4-CMA with full structural assignment. 
 
4. Discussion 
The combination of all applied techniques HPLD-PDA, GC-MS and 1H-NMR allowed to 
unequivocally identify the unknown substance as 4-CMA in a tablet confiscated at an 
international music festival. Since this seizure, which happened in August of 2015 (Figure 10, 
part A), several other cases were reported in the EU where 4-CMA was identified in seized drug 
samples: in November and December of 2015 respectively , light yellow tablets with a turtle logo 
containing 4-CMA were identified in respectively Romania and Austria (Figure 10, part B). 
Finally, in March 2016 a larger quantity of these tablets with turtle logo was identified by police 
services in Croatia.  
 
Figure 10. Ecstasy tablets containing 4-CMA, found in 2015 in Belgium (A) and elsewhere in 
Europe (B). 
 
 To estimate the potency of the tablet, a quantitative assessment of the 4-CMA concentration 
(performed with HPLC-PDA) indicated a dosage of approximately 98 mg 4-CMA (expressed as 
mg base per tablet).  
4-CMA is the para-chlorinated N-methylated derivative of amphetamine and was researched in 
the 1960’s as an appetite suppressant. During these studies, decreased levels of 5-
hydroxytryptamine (serotonin, 5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) were observed 
after the administration of p-chloroamphetamine and 4-CMA (10). 4-CMA was described by 
Patrick et al. and Pletscher et al. Notable was that the substance differed from other 
amphetamines by exhibiting only a slight central stimulant effect in both animals and humans, 
and that they acted like an antidepressant rather than a central stimulant. 4-CMA was briefly 
evaluated clinically as an antidepressant. It was also reported that 4-CMA was found to be a 
potent and long-lasting depleter of brain serotonin. Further investigation into the long-term 
effects of chloroamphetamines demonstrated that administration of 4-CMA caused a prolonged 
reduction in the levels of 5-HT and the activity of tryptophan hydroxylase in the brain. One 
month after injection of a single dose of the drug, both 5-HT and tryptophan hydroxylase activity 
were still maximally reduced (11–14). It has been compared to methamphetamine in normal 
subjects. No major physiological side effects were noted. Ultimately it was discovered that 4-
CMA is neurotoxic, specifically acting at the serotonergic neurotransmission system (15–18). 
Hence, clinical research in humans was halted. Dosages used in lab animals were 1-2 mg/kg. 
Human clinical dosages of 4-CMA used during the research as an antidepressant amounted to 80 
mg daily (divided into three doses) (19), comparable to what was found in the 4-CMA tablet in 
Belgium (approximately 98 mg/tablet). Since a specific antidote is lacking treatment of 
overdoses would be symptomatic.  
 
In the absence of empirical experimental clinical evidence, prof. David Nichols would predict 4-
CMA to be a stimulant and hyperthermic agent with a psychopharmacology similar to MDMA, 
but more potent, and also neurotoxic. 4-CMA might have a longer duration of action compared 
to MDMA (which lasts 4-5 hours) because it is less susceptible to metabolism. Acute toxicity of 
this compound (hyperthermia, dehydration) was the first concern of Dr. Nichols (20).  
 
Summarizing the receptor actions of 4-CMA, we estimate that clinical effects of 4-CMA will be 
a combined result of motor activating effects mediated by NA potentiation, and mood-improving 
effects caused largely by 5-HT potentiation. In practice, these include stimulant effects (such as 
increased energy and stimulation, euphoria) and feelings of wellbeing and possibly 
empathogenic effects comparable to those of MDMA, attributable to the serotonergic properties 
of 4-CMA (19). Based on rodent data it is believed that 4-CMA will be more potent than MDMA 
and will likely have a longer duration of action, with a psychopharmacology similar to MDMA 
(20). 
 From available literature and expert discussion, we estimate that the health risks for 4-CMA 
could include both acute and more prolonged long-term effects. Theoretically acute health risks 
would be comparable to those observed for MDMA, PMMA and 4-MA, and would be mainly 
due to serotonin release, combined with noradrenergic stimulation. Potentially severe, possibly 
malignant hyperthermia would be a risk resulting from an induced serotonin syndrome. In 
addition to acute effects, literature suggests 4-CMA demonstrates neurotoxic properties resulting 
in permanent destruction of serotonergic neurons. Currently the clinical or biological 
implications of this neurotoxicity in humans remain unknown. Serotonergic neurotransmission 
being implicated, it stands to reason that long-term exposure and/or damage could potentially 
include depression. In addition, no information is available regarding the time of manifestation 
of these symptoms; late onset of symptoms of induced neurotoxicity is a possibility.  
 
5. Conclusions 
To the author’s best knowledge, this is the first report in published literature confirming the 
presence of 4-CMA in a seized ecstasy tablet. Conclusive identification and analytical 
characterization were performed using HPLC-PDA, GC-MS (including TMS and TFA 
derivatives) and 1H-NMR. Available literature and discussion with experts suggests neurotoxic 
properties for 4-CMA, the effects of which on the human body are currently unknown. The drug 
is typically advertised on the web as a ‘research chemical’ and offered for sale as either tablets or 
powder. No intoxications or fatalities involving the use of 4-CMA were found in literature; 
Considering that after this initial detection several other tablets containing 4-CMA were 
identified in different parts of Europe, it stands to reason that some people will have consumed 
these tablets. In clinical cases with observed neurotoxicity after (prolonged) drug abuse, 
especially ecstasy, and in the absence of other contributing factors, professionals could consider 
the potential (past) consumption of tablets containing 4-CMA when assessing patient and case 
history. After March 2016 no tablets containing 4-CMA were reported again. We estimate that 
tablets containing 4-CMA were present on the European market for about six months (summer 
2015 – spring 2016).  
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